EURO Pharma

Orient EuroPharma (OEP) is a leading multinational pharmaceutical company headquartered in Taiwan, specializing in the development, manufacturing, and commercialization of specialty medicines across the Asia-Pacific region. Founded in 1982, the company has evolved from a distributor into an integrated pharmaceutical group with robust R&D capabilities focused on oncology, central nervous system (CNS) disorders, and cardiovascular health. OEP operates through key subsidiaries including Orient Pharma, which focuses on innovative drug delivery technologies like transdermal patches and controlled-release formulations, and OP NanoPharma, which develops advanced nanoparticle-based cancer therapies. The company maintains a diverse pipeline of late-stage programs, including a Phase 3 Alzheimer's patch and a Phase 3 micellar cisplatin for pancreatic cancer, while also securing strategic partnerships with global biotech firms like Rakuten Medical and George Medicines. With a strong commercial footprint in Taiwan, Southeast Asia, and China, OEP is a significant player in the regional life sciences landscape.